Table 1. Marketing to Physicians Involving Stimulant Products, per the Open Payment Program Database (January 1, 2014, to December 31, 2018).
| Characteristic | Payments, No. (%) | Total Payment Amount, $ | Payment, Median (IQR), $ |
|---|---|---|---|
| Total | 591 907 (100.0) | 20 101 250 (100.0) | 14 (12-18) |
| Type of marketing | |||
| Food and beverage | 578 105 (97.7) | 9 988 670 (49.7) | 14 (12-18) |
| Travel and lodging | 7142 (1.2) | 2 049 398 (10.2) | 178 (53-361) |
| Speaking fees | 1806 (0.3) | 3 834 205 (19.1) | 2000 (950-2570) |
| Honoraria | 1579 (0.3) | 2 454 854 (12.2) | 1500 (1000-2025) |
| Consulting fees | 438 (0.1) | 1 563 676 (7.8) | 3045 (1920-3750) |
| Other paymentsa | 2837 (0.5) | 210 446 (1.0) | 38 (20-91) |
| Stimulant productb | |||
| Vyvanse | 274 502 (46.4) | 7 076 729 (35.2) | 14 (12-17) |
| Quillivant | 80 086 (13.5) | 2 250 682 (11.2) | 15 (13-19) |
| Mydayis | 65 356 (11.0) | 3 085 987 (15.4) | 15 (12-19) |
| Evekeo | 60 969 (10.3) | 1 739 565 (8.7) | 13 (11-15) |
| Adzenys | 51 269 (8.7) | 2 199 064 (10.9) | 15 (13-19) |
| Dyanavel | 28 817 (4.9) | 1 948 762 (9.7) | 15 (12-19) |
| Aptensio | 19 925 (3.4) | 1 469 859 (7.3) | 16 (13-20) |
| Other stimulantsc | 30 490 (5.2) | 851 566 (4.2) | 15 (12-18) |
Abbreviation: IQR, interquartile range.
a
Includes payments labeled as education or other gifts.
b
Some payments involved multiple stimulant products; totals may add to more than 100%.
c
Includes Cotempla, Daytrana, Quillichew, Zenzedi, Focalin, Precentra, Adderall, Ritalin, and Concerta.